Symmetry Medical to Present at the 23rd Annual Piper Jaffray Health Care Conference

* Reuters is not responsible for the content in this press release.

Fri Nov 18, 2011 4:05pm EST

WARSAW, Ind., Nov. 18, 2011 (GLOBE NEWSWIRE) -- Symmetry Medical Inc.
(NYSE:SMA), a leading global source of innovative medical device solutions,
including surgical instruments, orthopedic implants, and sterilization cases and
trays, announced today that Thomas J. Sullivan, President and Chief Executive
Officer and Fred L. Hite, Senior Vice President and Chief Financial Officer, are
scheduled to participate in a fireside chat presentation at the 23nd Annual
Piper Jaffray Health Care Conference in New York City.

Event:  23rd Annual Piper Jaffray Health Care Conference

Date:    Tuesday, November 29, 2011

Time:    2:00 p.m. ET

A live webcast of the presentation will be available on Symmetry Medical's
website at www.symmetrymedical.com. A replay of the webcast will be available
for 30 days after the date of the presentation.

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading global source of innovative medical device
solutions, including surgical instruments, orthopedic implants, and
sterilization cases and trays. The Company's thousands of Teammates provide
design, development and worldwide production capabilities for these products to
customers in the orthopedic industry, other medical device markets, and
specialized non-healthcare markets. Symmetry's trusted reputation and brands,
broad Intellectual Property portfolio and commitment to innovation enable it to
collaborate with hundreds of global medical device manufacturers as well as
thousands of hospitals to provide solutions for today's needs and tomorrow's
growth.

CONTACT: Symmetry Medical Inc.
         Fred L. Hite
         Senior Vice President
         Chief Financial Officer
         (574) 371-2218

         Investors:
         The Ruth Group
         Zack Kubow
         (646) 536-7020
         zkubow@theruthgroup.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.